Compugen (CGEN) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Compugen (CGEN) has outperformed Coherus Oncology (CHRS) over the past year, gaining 17.1% versus a loss of 40.9%. Over five years, CGEN leads with a -66.7% price change compared with -94.1% for CHRS. Compugen is the larger company by market cap ($200.8 million vs $165.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | CHRS |
|---|---|---|
| Share price | $2.12 | $1.07 |
| Market cap | $200.82M | $165.32M |
| 1-day change | -1.40% | +5.94% |
| YTD return | +38.56% | -28.87% |
| 1-year return | +17.13% | -40.94% |
| 5-year return | -66.67% | -94.06% |
| P/E ratio (TTM) | 5.58 | — |
| EPS (TTM) | $0.38 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.24 | $2.62 |
| 52-week low | $1.43 | $0.974 |
| Distance from 52-week high | -34.57% | -59.10% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +116.98% | +624.30% |
| Average volume | 244.17K | 1.16M |
| Shares outstanding | 94.72M | 154.50M |
| Employees | 75 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed CHRS by 58.1 percentage points over the past year.
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
CGEN vs CHRS FAQ
Which is bigger, Compugen or Coherus Oncology?
Compugen (CGEN) is larger, with a market capitalization of $200.82M compared with $165.32M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CGEN or CHRS?
CGEN returned +17.13% over the past 12 months, compared with -40.94% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Compugen and Coherus Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.